Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 40Biopsy 32Magnetic Resonance Spectroscopy 26pembrolizumab 20Nivolumab 10trastuzumab deruxtecan 9Paclitaxel 9Carboplatin 9Radiosurgery 7Irinotecan 7Gemcitabine 7X-Rays 6Pemetrexed 6Leucovorin 6Ipilimumab 6Fulvestrant 6Fluorouracil 6Cetuximab 6Bevacizumab 6palbociclib 5Taxes 5Oxaliplatin 5Cisplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Letrozole 4CTLA-4 Antigen 4ribociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × 18-O-demethylcervinomycin A2 × 30 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡